Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<IPO>CiDi, InSilico Medicine Submit Listing Applications to HKEX
Recommend 7 Positive 8 Negative 3 |
||||
|
||||
|
CiDi, a Chinese smart commercial vehicle company, and InSilico Medicine, an AI-driven biotechnology company, have submitted listing applications to HKEX (00388.HK). InSilico Medicine had previously submitted applications in June 2023, March 2024, and May 2025, but all of them have since lapsed. According to the application documents, InSilico Medicine's revenue fell by 54% from USD59.689 million in 1H24 to USD27.456 million in 1H25. During the period, it logged a loss of USD19.215 million, compared to a profit of USD8.03 million in the same period last year. As for CiDi, its revenue for 1H25 increased by 57.9% YoY to RMB408 million, while its loss expanded to RMB455 million, compared to a loss of RMB123 million in the same period last year. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
